Macrophage Inhibitor CNI-1493 Prevents Lung Metastases in Ewing’s Sarcoma

Ewing’s Sarcoma (ES) is the second most common malignancy of bone in children, and the prognosis remains poor in patients with metastatic disease. In our increasing effort to identify mechanisms of metastasis, we have begun to look at macrophage activity which is now recognized as critical to the metastatic spread of solid tumors. The macrophage inhibitor, CNI-1493, may inhibit lung metastases and invasive capacity, potentially leading to new anti-metastatic strategies to treat Ewing's sarcoma and other pediatric solid tumors.

Video Comments

Log in to post a comment about this video.

Video Options

    • Add to Bookmarks